Area of research
Epidemiology · Infectious Diseases
Research interest
Research interests include Infective Endocarditis Diagnosis and Management, Mycobacterium research and diagnosis, Antimicrobial Resistance in Staphylococcus, and Tuberculosis Research and Epidemiology.
Safety, Efficacy, and Immunogenicity of a Multivalent Adjuvanted S. aureus Vaccine in Adults with Recent Skin And Soft Tissue Infections: An Observer-blind, Randomized, Placebo-controlled, Multinational Phase 1/2 Trial.
<i>Staphylococcus aureus</i> Strains With a Negative Coagulase Tube Test are Associated With Staphylocoagulase Genotypes.
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Patient-Reported Outcomes Following Periprosthetic Joint Infection of the Hip and Knee: A Longitudinal, Prospective Observational Study.
Prevalence, risk factors, and outcomes of secondary infections among hospitalized patients with COVID-19 or post-COVID-19 conditions in Victoria, 2020-2023.
Act fast, stop COVID: The successful implementation of the first decentralised Victorian COVID-19 contact tracing and monitoring unit.
Emergence of carbapenemase-producing Enterobacterales (CPE) in patients with severe COVID-19 infection and successful control in intensive care.
The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions
Early Oral Antibiotic Switch in <i>Staphylococcus aureus</i> Bacteraemia: The <i>Staphylococcus aureus</i> Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol
The<i>Staphylococcus aureus</i>Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
Environmental risk factors associated with the presence of<i>Mycobacterium ulcerans</i>in Victoria, Australia
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
Pediatric <i>Staphylococcus aureus</i> Bacteremia: Clinical Spectrum and Predictors of Poor Outcome
Psychiatrists can treat hepatitis C.
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study
In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance
Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Mucormycosis in Australia: contemporary epidemiology and outcomes
Efficacy, Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine in Adults Aged 60 Years and Older: Results From the ZOE-50 and ZOE-70 Efficacy Studies
Quality-of-Life Impact of an Investigational Subunit-Adjuvanted Herpes Zoster Vaccine in Adults ≥50 Years of Age
Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality
Candida Infective Endocarditis: an Observational Cohort Study with a Focus on Therapy
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
Impact of Early Valve Surgery on Outcome of Staphylococcus aureus Prosthetic Valve Infective Endocarditis: Analysis in the International Collaboration of Endocarditis–Prospective Cohort Study
Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014